Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07363694 | A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease | PHASE2 | RECRUITING | 1,156 | — | — | Feb 11, 2026 | Jan 16, 2031 | Mar 27, 2026 | 32 | United States, Canada +1 |
FEV1 is the maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration. FEV1 is obtained from spirometry.
Exacerbation of Chronic Obstructive Pulmonary Disease (ECOPD) are sudden worsening of respiratory symptoms that significantly worsen lung function and quality of life.
| Arm | Type | Description |
|---|---|---|
| Phase 2 Treatment Arm A | EXPERIMENTAL | - |
| Phase 2 Treatment Arm B | EXPERIMENTAL | - |
| Phase 2 Treatment Arm C | PLACEBO_COMPARATOR | - |
| Phase 3 Treatment Arm A | EXPERIMENTAL | - |
| Phase 3 Treatment Arm B | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| PF-07275315 dose 1 | DRUG | SC injection dose 1 |
| PF-07275315-dose 2 | DRUG | SC injection dose 2 |
| Placebo | DRUG | SC injection matched |
| PF-07275315-dose 3 | DRUG | SC injection dose 3 |
Key Inclusion Criteria: * Diagnosis of chronic obstructive pulmonary disease (COPD) for at least 12 months (based on Global Initiative for Chronic Obstructive Lung Disease \[GOLD\] definition). * Spirometry values (post-bronchodilator forced expiratory volume in 1 second \[FEV1\]/forced vital capac...